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We present a case of Candida dubliniensis meningitis 
that developed 2 months after apparently successful treat-
ment of an episode of C. dubliniensis candidemia in a heart-
lung transplant recipient in Australia. This case highlights 
the importance of follow-up in patients with candidemia or 
disseminated infection, especially in immunosuppressed 
patients.
T
he patient, a 48-year-old man, was admitted to St Vin-
cent’s Hospital, Sydney, Australia, in February 2007 
for a heart and bilateral lung transplant for a familial dilated 
cardiomyopathy with severe secondary pulmonary hyper-
tension. The operation was uneventful. Postoperatively, 
the patient was admitted to the intensive care unit (ICU), 
and immune-suppressive agents (cyclosporine, methyl-
prednisolone, azathioprine) and prophylaxis against oppor-
tunistic infections (gancliclovir, cotrimoxazole, nebulized 
amphotericin B at 10 mg twice a day) were begun. After 
an initial loading dose of 70 mg caspofungin, 50 mg daily 
was continued for treatment of infection with a Candida 
spp. isolated from a blood culture on postoperative day 9. 
Standard phenotypic methods and API 32C (bioMérieux, 
Marcy l’Etoile, France) conﬁ  rmed a C. dubliniensis with 
99% probability. The same organism was grown from pleu-
ral ﬂ  uid (empyema) and urine (candiduria, normal renal 
imaging).
Although the isolate’s ﬂ   uconazole MIC was 0.025 
μg/mL (YeastOneYO8, TREK Diagnostic Systems, Ltd., 
East Grinstead, UK), caspofungin (MIC 0.06 μg/mL) was 
administered because of ongoing dialysis-dependent renal 
impairment and abnormal liver function test results related 
to hepatic ischemia. The transesophageal echocardiogram 
results were normal. Ophthalmology review failed to dem-
onstrate endophthalmitis. Candidemia clearance was con-
ﬁ  rmed by negative blood cultures (days 7, 8, and 10 of ca-
spofungin). Repeat urine cultures were sterile. A chest and 
abdominal computed tomography scan (on day 32 of anti-
fungal therapy) showed a normal liver, spleen, and renal 
tract as well as bilateral reaccumulated pleural effusions af-
ter removal of the intercostal chest drains. However, micro-
biologic cure was conﬁ  rmed by a repeat pleural aspiration. 
In addition, chest radiographs before discharge conﬁ  rmed 
total resolution of the pleural effusion. HIV serologic test 
results were negative. Dose adjustments for cyclosporine 
and prednisolone were the only changes instituted to the 
immune-suppressive agents during the patient’s illness. 
The oral prednisolone was slowly tapered from an initial 
50 mg/day to a maintenance dose of 10 mg/day in March. 
The patient was discharged from intensive care on day 14 
and from hospital 52 days posttransplant, in April 2007; he 
was not receiving any antifungal agents on discharge. The 
total duration of therapy for disseminated candidiasis was 
40 days, consisting of caspofungin (28 days) followed by 
ﬂ  uconazole (400 mg/day for 12 days).
The patient was seen 2 months later, in June 2007, with 
a 3-week history of progressive headache, early morning 
nausea, vomiting, and weight loss. There was no history of 
fevers or rigors. Examination showed no neck stiffness, pho-
tophobia, or focal neurologic signs. A magnetic resonance 
imaging scan showed enhancing meninges consistent with 
meningitis. A lumbar puncture yielded clear cerebrospinal 
ﬂ  uid (CSF) with 116 x 106 leukocytes/L (79% neutrophils 
and 14% lymphocytes), an elevated protein level of 1,224 
mg/L (normal range 0–400 mg/L), and a reduced glucose 
level of 1.7mmol/L (normal range 2–4 mmol/L) with a con-
current serum glucose level of 5.5 mmol/L(normal range 
3.0–7.8 mmol/L). No fungi were seen on Gram stain. At 
24 hours, the primary plates and broth culture grew a bud-
ding yeast that was identiﬁ  ed with a 99% probability as C. 
dubliniensis on API 32C (bioMérieux).
Molecular conﬁ   rmation was performed. Genomic 
DNA was extracted from the culture by using a QIAamp 
DNA Mini Kit (QIAGEN, Hilden, Germany). C. dublini-
ensis–speciﬁ  c PCR and internal transcribed spacer (ITS) 
regions of the rRNA gene complex were ampliﬁ  ed as 
previously described (1,2). The PCR products were pu-
riﬁ  ed for sequencing by using the QIAquick PCR Puri-
ﬁ  cation Kit (QIAGEN). The sequences were compared 
to those available in the GenBank databases by using the 
BLASTN program (www.ncbi.nlm.nih.gov/BLAST). The 
ITS gene sequences generated showed a 100% similarity 
to strains of C. dubliniensis (GenBank accession nos. DQ 
355947, AF405231, AJ865083, AJ865082, AJ865081). 
Unfortunately, the initial blood culture isolate was no 
longer available for comparative sequencing. However, 
the API 32C and susceptibility proﬁ  les (YeastOne YO8) 
were identical, a ﬁ  nding that suggested that the 2 strains 
were identical.
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tient was not receiving antifungal therapy) were negative. 
A chest radiograph was clear with no evidence of effusion. 
A transthoracic echocardiogram and ophthalmology review 
were clear for signs of metastatic candidiasis. Fluconazole 
therapy was begun, and the patient made a full recovery.
Candida is an important pathogen in critically ill pa-
tients. Yeasts account for 8%–10% of nosocomial blood 
culture isolates with an increased incidence in immune-
suppressed patients (3). Multiple species cause candidemia; 
however, 5 species—C. albicans, C. glabrata, C. parapsi-
losis, C. tropicalis, and C. krusei—account for >95% of all 
cases worldwide, including Australia (3,4).
C. dubliniensis shares phenotypic characteristics with 
C. albicans on routine laboratory testing and therefore was 
only recognized as a novel species with the advent of mo-
lecular testing. It remains an uncommon isolate, account-
ing for <2% of all candidemias (4). The original reports 
of C. dubliniensis were in mucosal disease HIV-infected 
patients and patients not infected with HIV (5). Subsequent 
candidemia was reported from Europe, North America, and 
Australia in a wide variety of patients with multiple seri-
ous medical problems (6–9). C. dubliniensis candidemia in 
solid organ transplant recipients is rare (10).
Meningitis is a rare manifestation of disseminated 
disease. Risk factors for meningitis are similar to those as-
sociated with invasive candidiasis (4). The risk of devel-
oping this complication is unknown. However, 2 speciﬁ  c 
patients groups, premature neonates and neurosurgical pa-
tients, are at increased risk (11,12). C. albicans accounts 
for 70%–100% of all meningitis isolates. Other reported 
species include C. glabrata, C. tropicalis, C. parapsilop-
sis, and C. lusitaniae (4). Our patient represents, to our 
knowledge, the ﬁ  rst documented case of C. dubliniensis 
meningitis.
Symptoms of fungal meningitis include fever, head-
ache, altered mental status, and meningism. Focal neuro-
logic signs are rare. The frequency and severity of symp-
toms vary between patient groups. In HIV-infected patients, 
fever (86%), headache (93%), and meningism (50%) oc-
curred in most patients; by contrast, patients with neuro-
surgical devices had lower rates of meningism (18%) and 
headaches (18%) but comparable rates of fever (82%) (10). 
Candida meningitis in solid organ transplant recipients is 
extremely rare; symptoms are probably modiﬁ  ed by the de-
gree of immune-suppression, as illustrated in our patient.
The diagnosis of meningitis is established by a positive 
CSF culture. Multiple CSF specimens may be required. 
CSF parameters are variable, with a mild lymphocytic or 
polymorphonuclear pleocytosis and an increased protein 
level. Fungal elements are generally not seen. Thus, CSF 
abnormalities are indistinguishable from cryptococcal, tu-
berculous, and some bacterial meningitides (13).
Delayed complications occur after candidemia. Thus, 
consensus guidelines suggest 3 months’ follow-up to detect 
these complications (14). Delayed meningeal infection fol-
lowing C. albicans candidemia has been documented; the 
meningitis occurred 3 months after “successful” therapy 
(15).
Our patient received curative therapy (negative repeat 
cultures) for disseminated candidiasis (candidemia, candi-
duria, and empyema) with caspofungin and ﬂ  uconazole of 
adequate duration. Despite this treatment, our patient had 
delayed meningitis 2 months after therapy. Whether the 
meningitis was secondary to re-infection or reactivation of 
latent infection is unclear. Caspofungin was the cornerstone 
of therapy, and reactivation is possible with this antifungal 
agent because it has poor CSF penetration. However, re-
infection cannot be excluded. 
In conclusion, we present a case of delayed C. dubli-
niensis meningitis. This case highlights the need for clini-
cians to be aware of possible delayed complications despite 
apparently successful therapy. Furthermore, routine fol-
low-up (at 3 months) should be considered for all patients 
following candidemia, especially immune-suppressed pa-
tients.
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